Biotinylated Human TNF-alpha Protein, His,Avitag™, active trimer (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
TNA-H82E3-25ug
$435.00
TNA-H82E3-200ug
$1740.00
ETA of in-stock products:2 business days

Product Details

  • Synonym

    DIF, TNF-alpha, TNFA, TNFSF2, cachexin, cachectin, TNFα

  • Source

    Biotinylated Human TNF-alpha, His,Avitag (TNA-H82E3) is expressed from human 293 cells (HEK293). It contains AA Val 77 - Leu 233 (Accession # NP_000585.2).

    Predicted N-terminus: Val 77

    Request for sequence
  • Molecular Characterization

    TNF-alpha Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 20.0 kDa. The protein migrates as 21 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    TNF-alpha SDS-PAGE

    Biotinylated Human TNF-alpha, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    TNF-alpha SEC-MALS

    The purity of Biotinylated Human TNF-alpha, His,Avitag (Cat. No. TNA-H82E3) is more than 90% and the molecular weight of this protein is around 55-75 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     TNF-alpha ELISA

    Immobilized Humira at 5 μg/mL (100 μL/well) can bind Biotinylated Human TNF-alpha, His,Avitag (Cat. No. TNA-H82E3) with a linear range of 0.1-3 ng/mL (QC tested).

    Protocol
  •  TNF-alpha ELISA

    Immobilized Human TNFR2, His Tag (Cat. No. TN2-H5227) at 5 μg/mL (100 μL/well) can bind Biotinylated Human TNF-alpha, His,Avitag (Cat. No. TNA-H82E3) with a linear range of 0.6-10 ng/mL (Routinely tested).

    Protocol
  •  TNF-alpha ELISA

    Immobilized Human TNFR1, Fc Tag (Cat. No. TN1-H5251) at 5 μg/mL (100 μL/well) can bind Biotinylated Human TNF-alpha, His,Avitag (Cat. No. TNA-H82E3) with a linear range of 0.2-5 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-CELL BASE

     TNF-alpha CELL

    Biotinylated Human TNF-alpha, His,Avitag (Cat.No. TNA-H82E3) induces cytotoxicity effect on the WEH1-13VAR cells in the presence of the metabolic inhibitor actinomycin D. The EC50 for this effect is 0.029-0.052 ng/mL (Routinely tested).

    Protocol
  •  TNF-alpha CELL

    Neutralization assay shows that the cytotoxicity effect of Biotinylated Human TNF-alpha, His,Avitag (Cat. No. TNA-H82E3) was inhibited by increasing concentration of Adalimumab. The concentration of TNF-alpha used is 1 ng/mL. The IC50 is 7 ng/mL (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

Tumor necrosis factor alpha (TNFα) is a cytokine produced primarily by monocytes and macrophages. It is found in synovial cells and macrophages in the tissues.The primary role of TNFα is in the regulation of immune cells. TNFα is able to induce apoptotic cell death, to induce inflammation, and to inhibit tumorigenesis and viral replication. Dysregulation of TNFα production has been implicated in a variety of human diseases, including major depression, Alzheimer's disease and cancer. Recombinant TNFα is used as an immunostimulant under the INN tasonermin. TNFα can be produced ectopically in the setting of malignancy and parallels parathyroid hormone both in causing secondary hypercalcemia and in the cancers with which excessive production is associated.

Recent Advances

 
Drug Development Progress
  • English Name:

    Tumor necrosis factor α

  • Category:

  • Approved Drugs:

    68 Details

  • Drugs in Clinical Trials:

    74 Details

  • Highest Development Stage:

    Approved

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland